The objective of this study is to evaluate the safety and tolerability of 48 weeks subcutaneous dosing with LY2127399 for patients who have participated in a prior LY2127399 clinical study. At the end of the 48 week treatment period, patients will participate in a 24 week follow up period. Additional follow up after week 72 may continue to assess B cell recovery.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01253291?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
